Hologic Inc. (HOLX) announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology (breast tomosynthesis) with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer, across all breast tissue densities.
The Rose study found that the use of Hologic's 3D mammography resulted in a significant 38% drop in recall rates - from 8.7% to 5.5% (p < 0.001); An 11% drop in biopsy rates - from 15.2 to 13.5 per 1,000 screenings (p = 0.59); a 35% increase in cancer detection rates - from 4.0 to 5.4 per 1,000 screenings (p = 0.18).
The study population included 13,856 women who had received conventional 2D mammography screening exams and 9,499 women who elected to receive a Hologic 3D mammography screening exam. The images were interpreted by one of six radiologists with an average 12 years of reading experience.
"The findings in the Rose paper demonstrate that Hologic 3D mammograms overcome many of the limitations of conventional mammography, namely missed cancers and unnecessary recalls," said Peter Soltani, Hologic Senior Vice President and General Manager, Breast Health.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.